Press Resease

Stroke Diagnostics and Therapeutics Market by Diagnostics (Magnetic Resonance Imaging, Computed Tomography Scan, Electrocardiography Carotid Ultrasound, Cerebral Angiography and Others) by Therapeutics (Tissue Plasminogen Activator, Antiplatelet, Antihypertensive, and Anticoagulant) for Haemorrhagic Stroke and Ischemic Stroke - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2026

Published Date: 19-Dec-2016 Category: Medical Device Report Format : PDF Pages: 110 Report Code: ZMR-574 Status : Published

According to the report, the Stroke Diagnostics and Therapeutics Market accounted for USD 27.08 Billion in 2019 and is expected to reach USD 43.48 Billion by 2026, growing at a CAGR of around 7% between 2020 and 2026.

Description

The report covers forecast and analysis for the stroke diagnostics and therapeutics market on a global and regional level. The study provides historic datawith a forecast from 2016 to 2026 based on revenue (USD Billion). The study includes drivers and restraints for the stroke diagnostics and therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the stroke diagnostics and therapeutics market on a global level.

This report offers comprehensive coverage on global stroke diagnostics and therapeutics market along with, market trends, drivers, and restraints of stroke diagnostics and therapeutics market. This report included a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the stroke diagnostics and therapeutics market has also been included. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. This report is prepared using data sourced from in-house databases, secondary and primary research team of industry experts.

The study provides a decisive view on the stroke diagnostics and therapeutics market by segmenting the market based on diagnostics, therapeutics, application, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. The diagnostics market covered under this study includes magnetic resonance imaging, computed tomography scan, electrocardiography, and carotid ultrasound. The therapeutics segmentation includes tissue plasminogen activator, antiplatelet, antihypertensive and anticoagulant. The application segmentation includes haemorrhagic stroke and ischemic stroke. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further sub-segmented into the U.S., U.K., Germany, France, Japan, China, India, and Brazil.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global stroke diagnostics and therapeutics market include Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cordis Corporation, Koninklijke Philips N.V., GE Healthcare, Siemens AG, Stryker Corporation, Genentech, Inc. and Merck & Co., Inc

This report segments the global stroke diagnostics and therapeutics market as follows:

Global Stroke Diagnostics and Therapeutics Market:  Diagnostics Analysis

  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography Scan (CT scan)
  • Electrocardiography
  • Carotid Ultrasound
  • Cerebral Angiography
  • Others

Global Stroke Diagnostics and Therapeutics Market: Therapeutics Analysis

  • Tissue Plasminogen Activator
  • Antiplatelet
  • Antihypertensive
  • Anticoagulant

Global Stroke Diagnostics and Therapeutics Market: Application Analysis

  • Haemorrhagic Stroke
  • Ischemic Stroke

Global Stroke Diagnostics and Therapeutics Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East And Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Stroke Diagnostics and Therapeutics Market, 2016-2026 (USD Billion)
    • 2.2. Stroke Diagnostics and Therapeutics Market: Snapshot
  • Chapter 3. Stroke Diagnostics and Therapeutics Market - Industry Analysis
    • 3.1. Stroke Diagnostics and Therapeutics Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidences Of Diabetes And Large Number Of Tobacco Users
    • 3.3. Restraints
      • 3.3.1. High Cost Of Treatment
    • 3.4. Opportunity
      • 3.4.1. Covering Untapped Market
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Diagnostics
      • 3.6.2. Market attractiveness analysis By Therapeutics
      • 3.6.3. Market attractiveness analysis By Application
      • 3.6.4. Market attractiveness analysis by Region
  • Chapter 4. Stroke Diagnostics and Therapeutics Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Stroke Diagnostics and Therapeutics Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Diagnostics launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Stroke Diagnostics and Therapeutics Market -Diagnostics Analysis
    • 5.1. Global Stroke Diagnostics and Therapeutics Market overview: By Diagnostics type
      • 5.1.1. Global Stroke Diagnostics and Therapeutics Market share, By Diagnostics,2019 and 2026
    • 5.2. Magnetic Resonance Imaging
      • 5.2.1. Global Stroke Diagnostics and Therapeutics Market by Magnetic Resonance Imaging, 2016-2026 (USD Billion)
    • 5.3. Computed Tomography Scan
      • 5.3.1. Global Stroke Diagnostics and Therapeutics Market by Computed Tomography Scan, 2016-2026 (USD Billion)
    • 5.4. Electrocardiography Carotid Ultrasound
      • 5.4.1. Global Stroke Diagnostics and Therapeutics Market by Electrocardiography Carotid Ultrasound, 2016-2026 (USD Billion)
    • 5.5. Cerebral Angiography
      • 5.5.1. Global Stroke Diagnostics and Therapeutics Market by Cerebral Angiography, 2016-2026 (USD Billion)
    • 5.6. Others
      • 5.6.1. Global Stroke Diagnostics and Therapeutics Market by others, 2016-2026 (USD Billion)
  • Chapter 6. Global Stroke Diagnostics and Therapeutics Market -Therapeutics Analysis
    • 6.1. Global Stroke Diagnostics and Therapeutics Market overview: By Therapeutics
      • 6.1.1. Global Stroke Diagnostics and Therapeutics Market share, By Therapeutics, 2019 and 2026
    • 6.2. Tissue Plasminogen Activator
      • 6.2.1. Global Stroke Diagnostics and Therapeutics Market By Tissue Plasminogen Activator, 2016-2026 (USD Billion)
    • 6.3. Antiplatelet
      • 6.3.1. Global Stroke Diagnostics and Therapeutics Market By Antiplatelet, 2016-2026 (USD Billion)
    • 6.4. Antihypertensive
      • 6.4.1. Global Stroke Diagnostics and Therapeutics Market By Antihypertensive, 2016-2026 (USD Billion)
    • 6.5. Anticoagulant
      • 6.5.1. Global Stroke Diagnostics and Therapeutics Market By Anticoagulant, 2016-2026 (USD Billion)
  • Chapter 7. Global Stroke Diagnostics and Therapeutics Market -Application Analysis
    • 7.1. Global Stroke Diagnostics and Therapeutics Market overview: By Application
      • 7.1.1. Global Stroke Diagnostics and Therapeutics Market share, By Application, 2019 and 2026
    • 7.2. Haemorrhagic
      • 7.2.1. Global Stroke Diagnostics and Therapeutics Market by Haemorrhagic, 2016-2026 (USD Billion)
    • 7.3. Ischemic Stroke
      • 7.3.1. Global Stroke Diagnostics and Therapeutics Market by Ischemic Stroke, 2016-2026 (USD Billion)
  • Chapter 8. Global Stroke Diagnostics and Therapeutics Market - Regional Analysis
    • 8.1. Global Stroke Diagnostics and Therapeutics Market overview: by Region
      • 8.1.1. Global Stroke Diagnostics and Therapeutics Marketshare, by Region, 2019 and 2026
    • 8.2. North America
      • 8.2.1. North America Stroke Diagnostics and Therapeutics Market, 2016-2026 (USD Billion)
      • 8.2.2. North America Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
      • 8.2.3. North America Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
      • 8.2.4. North America Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S.Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.2.5.2. The U.S.Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.2.5.3. The U.S.Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.2.6.2. Rest of North America Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.2.6.3. Rest of North America Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Stroke Diagnostics and Therapeutics Market, 2016-2026 (USD Billion)
      • 8.3.2. Europe Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
      • 8.3.3. Europe Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
      • 8.3.4. Europe Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.3.5. UK
        • 8.3.5.1. U.K.Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.3.5.2. U.K.Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.3.5.3. U.K. Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.3.6.2. France Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.3.6.3. France Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.3.7. Germany
        • 8.3.7.1. Germany Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.3.7.2. Germany Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.3.7.3. Germany Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of EuropeStroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.3.8.2. Rest of EuropeStroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.3.8.3. Rest of Europe Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Stroke Diagnostics and Therapeutics Market, 2016-2026 (USD Billion)
      • 8.4.2. Asia Pacific Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
      • 8.4.3. Asia Pacific Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
      • 8.4.4. Asia Pacific Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.4.5. China
        • 8.4.5.1. China Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.4.5.2. China Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.4.5.3. China Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.4.6. Japan
        • 8.4.6.1. Japan Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.4.6.2. Japan Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.4.6.3. Japan Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.4.7. India
        • 8.4.7.1. India Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.4.7.2. India Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.4.7.3. India Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.4.8.2. Rest of Asia Pacific Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.4.8.3. Rest of Asia Pacific Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Stroke Diagnostics and Therapeutics Market, 2016-2026 (USD Billion)
      • 8.5.2. Latin America Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
      • 8.5.3. Latin America Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
      • 8.5.4. Latin America Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.5.5.2. Brazil Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.5.5.3. Brazil Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
      • 8.5.6. Rest of LatinAmerica
        • 8.5.6.1. Rest of LatinAmerica Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
        • 8.5.6.2. Rest of LatinAmerica Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
        • 8.5.6.3. Rest of Latin America Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Stroke Diagnostics and Therapeutics Market, 2016-2026 (USD Billion)
      • 8.6.2. The Middle East and Africa Stroke Diagnostics and Therapeutics Market revenue, By Diagnostics,2016-2026 (USD Billion)
      • 8.6.3. The Middle East and Africa Stroke Diagnostics and Therapeutics Market revenue, By Therapeutics, 2016-2026 (USD Billion)
      • 8.6.4. The Middle East and Africa Stroke Diagnostics and Therapeutics Market revenue, By Application, 2016-2026 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1. Abbott Laboratories
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Diagnostics Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Medtronic plc
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Diagnostics Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Boston Scientific Corporation
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Diagnostics Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Cordis Corporation
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Diagnostics Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. Koninklijke Philips N.V.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Diagnostics Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. GE Healthcare
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Diagnostics Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. Siemens AG
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Diagnostics Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development
    • 9.8. Stryker Corporation
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Diagnostics Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Development
    • 9.9. Merck & Co., Inc.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Diagnostics Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Development

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Stroke Diagnostics and Therapeutics market. Zion Research has collected and analyzed key data belong to the global Stroke Diagnostics and Therapeutics market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Stroke Diagnostics and Therapeutics across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Stroke Diagnostics and Therapeutics industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Stroke Diagnostics and Therapeutics market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

A stroke is the medical emergency condition, seen mostly in elderly age patients. Strokes happen when blood flow to brain stops and brain cells begin to die. There are two kinds of stroke which include ischemic stroke and hemorrhagic stroke. Ischemic stroke is the most common type of stroke and is caused by a blood clot that blocks a blood vessel in the brain. The other stroke is called hemorrhagic stroke and is caused by a blood vessel that breaks and bleeds into the brain.

Globally, stroke diagnostics and therapeutics market have been accelerated by the large patient pool. Moreover, increasing the percentage of the geriatric population in western countries especially in Europe is the key driving factor for fueling the growth of stroke diagnostics and therapeutics market. Furthermore, hypertension, atrial fibrillation and coronary heart diseases are the supporting factors which promote the growth of stroke diagnostics and therapeutics market. However, the high cost of treatment directly affects the growth of stroke diagnostics and therapeutics market. Nonetheless, ongoing research and development in the healthcare sector technologies are expected to open growth avenues for the stroke diagnostics and therapeutics market over the years.

Based on diagnostics, the global stroke diagnostics and therapeutics market is segmented into five types: magnetic resonance imaging, computed tomography scan, electrocardiography, carotid ultrasound, cerebral angiography and others.  Magnetic resonance imaging dominates the diagnostic segment of stroke diagnostics and therapeutics market in 2019. Magnetic resonance imaging of the brain is a safe and painless test that uses a magnetic field and radio waves to produce detailed images of the brain and the brain stem.

Based on therapeutics, the global stroke diagnostics and therapeutics market is segmented into four types: tissue plasminogen activator, antiplatelet, antihypertensive, and anticoagulant. Anticoagulant is an immediate treatment given in the emergency room to reduce the likelihood of having another stroke. Anticoagulant prevents blood clots from forming. Injection of tissue plasminogen activator also called alteplase are given to stroke patients. An injection of TPA is usually given through a vein in the arm. This potent clot-busting drug needs to be given within 4.5 hours after stroke symptoms begin.

Based on application, the global stroke diagnostics and therapeutics market is segmented into two types: haemorrhagic stroke and ischemic stroke. Ischemic stroke dominated the application segment of stroke diagnostics and therapeutics market. Ischemic stroke is the most usual type of stroke which is caused by a blood clot that blocks a blood vessel in the brain. The most common cause problem is narrowing of the arteries in the neck or head. This is most often caused by atherosclerosis, or gradual cholesterol deposition in blood vessels.

Based on geographies, the global stroke diagnostics and therapeutics market is segmented into five types: North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. These segments are further bifurcated into the U.S., UK, Germany, France, China, Japan, India, and Brazil. North America held the largest share in the global stroke diagnostics and therapeutics market followed by Europe and Asia-Pacific. This growth of North America was attributed due to high literacy rate and more awareness regarding controlling the symptoms of strokes which include high blood pressure and high blood glucose level. In addition, this region also associated with advance research related to blood monitoring device. The stroke diagnostics and therapeutics market are expected to witness the highest growth in Asia-Pacific region in upcoming years due government initiatives, awareness, increasing demand of anticoagulant drug and excessive increase of health care.

The key participants operating in the global stroke diagnostics and therapeutics market include Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cordis Corporation, Koninklijke Philips N.V., GE Healthcare, Siemens AG, Stryker Corporation, Genentech, Inc. and Merck & Co., Inc.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social